Amy Duross Sells 477 Shares of BioLife Solutions (NASDAQ:BLFS) Stock

BioLife Solutions, Inc. (NASDAQ:BLFS) Director Amy Duross sold 477 shares of the company’s stock in a transaction that occurred on Wednesday, November 19th. The stock was sold at an average price of $24.50, for a total value of $11,686.50. Following the sale, the director owned 30,210 shares in the company, valued at approximately $740,145. This represents a 1.55% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Amy Duross also recently made the following trade(s):

• On Friday, November 21st, Amy Duross sold 1,000 shares of BioLife Solutions stock. The stock was sold at an average price of $26.00, for a total transaction of $26,000.00.
• On Thursday, November 20th, Amy Duross sold 4,523 shares of BioLife Solutions stock. The stock was sold at an average price of $24.51, for a total transaction of $110,858.73.

BioLife Solutions Trading Up 9.6%

Shares of BLFS traded up $2.33 during midday trading on Friday, reaching $26.53. The stock had a trading volume of 540,117 shares, compared to its average volume of 456,202. The firm has a market cap of $1.28 billion, a PE ratio of -221.06 and a beta of 1.97. The firm has a 50 day simple moving average of $26.36 and a 200-day simple moving average of $24.10. BioLife Solutions, Inc. has a one year low of $19.10 and a one year high of $29.62.

Wall Street Analyst Weigh In

Several research firms have issued reports on BLFS. Zacks Research upgraded BioLife Solutions from a “hold” rating to a “strong-buy” rating in a research note on Friday, November 7th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of BioLife Solutions in a research report on Wednesday, October 8th. Finally, HC Wainwright reissued a “buy” rating and issued a $32.00 price objective (up from $30.00) on shares of BioLife Solutions in a research report on Friday, August 8th. One equities research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $31.20.

Institutional Investors Weigh In On BioLife Solutions

Hedge funds and other institutional investors have recently made changes to their positions in the business. Amalgamated Bank increased its stake in BioLife Solutions by 3.5% during the 3rd quarter. Amalgamated Bank now owns 10,898 shares of the medical equipment provider’s stock worth $278,000 after acquiring an additional 366 shares during the period. Ameritas Investment Partners Inc. grew its holdings in shares of BioLife Solutions by 12.8% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 3,873 shares of the medical equipment provider’s stock worth $83,000 after purchasing an additional 441 shares in the last quarter. Louisiana State Employees Retirement System grew its holdings in shares of BioLife Solutions by 2.9% during the 3rd quarter. Louisiana State Employees Retirement System now owns 17,800 shares of the medical equipment provider’s stock worth $454,000 after purchasing an additional 500 shares in the last quarter. Isthmus Partners LLC increased its position in shares of BioLife Solutions by 0.4% in the second quarter. Isthmus Partners LLC now owns 132,125 shares of the medical equipment provider’s stock worth $2,846,000 after purchasing an additional 509 shares during the period. Finally, Sei Investments Co. raised its stake in BioLife Solutions by 0.5% in the first quarter. Sei Investments Co. now owns 117,999 shares of the medical equipment provider’s stock valued at $2,695,000 after purchasing an additional 547 shares in the last quarter. 93.24% of the stock is currently owned by institutional investors and hedge funds.

BioLife Solutions Company Profile

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.